EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2

Objective : We conducted a multicenter study in Akita Prefecture, Japan, to characterize the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RBV) therapy in Japanese patients infected with hepatitis C virus (HCV) genotype 2.Methods : All of the patients were infected with HCV genotype 2. Patients received 12 weeks of treatment with 400 mg of SOF daily plus weight-based RBV (600-1,000 mg daily).Results : A total of 170 patients were enrolled in this study, and 167 patients were followed for 12 weeks after its completion. Among our patients, 28.2% (48/170) had liver cirrhosis (LC). Overall, 159 patients achieved a sustained virologic response for 12 weeks (SVR12), while 8 showed virologic failure. There were no significant differences in the rates of SVR12 between the chronic hepatitis (CH) and LC patients. No significant differences were noted between the CH and LC patients in the rates of any adverse events.Conclusion : We found that SOF plus RBV treatment resulted in high rates of SVR12 with a favorable safety and tolerability profile, including patients with cirrhosis

EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1

AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1.METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016.　We followed them until 24 weeks after the end of treatment.RESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%.　In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate.　In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate.　The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients.　10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom.　Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events.CONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events